Molecular Oncology Program

分子肿瘤学计划：摘要/摘要 HDFCCC分子肿瘤学项目（MO）的目标是发现、开发和翻译新的肿瘤学分子。 预防和治疗策略以及生物标志物。这是通过从基础研究到 科学在实验台和计算机的临床应用和背部，并通过专注于弥合差距 科学家和临床研究人员之间，从实验室到初创公司再到床边。所有MO计划 活动反映了HDFCCC的跨领域主题，即影响力发现（主题1），有效翻译 （主题2）和执行与传播（主题3），并得到资源和 由HDFCCC提供的协作环境。MO是一个新的研究计划，因为以前的竞争 退款中心范围内的研究计划重新调整现在允许MO成员在周围进行互动 诊断和治疗的重点是信号通路和表观遗传学，以及治疗， 突变导向但组织不可知，因此跨越多个学科并连接临床医生， 流行病学家和基础科学家。具体而言，MO成员的研究重点是（1）研究 遗传学对癌症易感性、进展和治疗反应的影响;（2）调节 治疗益处;和（3）开发工具和技术来剖析肿瘤和宿主环境网络。

Molecular Oncology Program: Summary/Abstract The goal of the HDFCCC Molecular Oncology Program (MO) is to discover, develop, and translate novel preventive and therapeutic strategies and biomarkers. This is done through research that spans from basic science at the bench and computer to clinical applications and back, and by focusing on bridging the gap between scientists and clinical researchers, and from bench to start-up company to bedside. All MO Program activities reflect the HDFCCC’s cross-cutting themes of Impactful Discovery (Theme 1), Effective Translation (Theme 2), and Implementation and Dissemination (Theme 3) and are bolstered by the resources and collaborative environment provided by the HDFCCC. MO is a new research program since the prior competing renewal. The Center-wide realignment of research programs now allows MO members to interact around diagnostics and therapies focused on signaling pathways and epigenetics, as well as on therapies that are mutation-directed but tissue-agnostic, thus spanning multiple disciplines and connecting clinicians, epidemiologists, and basic scientists. Specifically, MO member research focuses on (1) studying the impact of genetics on cancer susceptibility, progression, and therapeutic response; (2) modulating signaling pathways for therapeutic benefit; and (3) developing tools and technologies to dissect tumor and host environment networks.